RAPT Therapeutics
Stock Forecast, Prediction & Price Target
RAPT Therapeutics (RAPT) stock Price Target by analysts
$2
Potential downside: -81.27%
RAPT Therapeutics price prediction
What is RAPT Therapeutics stock analysts` prediction?
RAPT Therapeutics stock forecast: Based on 2 Wall Street analysts` predicted price targets for RAPT Therapeutics in the last 3 months, the avarage price target is $2, with a high forecast of $NaN. The average price target represents a -81.27% change from the last price of $10.68.
Disclaimer: This is not investment advice. Don't use price targets as the only investment indicator. Always remember to do your own thorough research and due diligence before making an investment decision.
RAPT Therapeutics stock Price Target by analysts
Full breakdown of analysts given RAPT Therapeutics price targets
| Analyst name & company | Analyst win rate | Publish date | Price target | Price when posted | Source | Historical targets |
|---|---|---|---|---|---|---|
Alex Thompson Stifel Nicolaus | 0% 0/1 | 11 months ago | $2 -81.27% downside | $1.74 | StreetInsider | Previous targets (0) |
Thomas Smith Leerink Partners | 0% 0/1 | 11 months ago | $2 -81.27% downside | $1.74 | StreetInsider | Previous targets (0) |
Unknown Guggenheim | N/A | over 2 years ago | $55 414.98% upside | $19.83 | Benzinga | N/A |
Unknown Wells Fargo | N/A | over 2 years ago | $48 349.43% upside | $19.5 | Benzinga | N/A |
Edward Tenthoff Piper Sandler | 0% 0/1 | almost 3 years ago | $33 208.98% upside | $16.48 | TheFly | Previous targets (0) |
Unknown Goldman Sachs | N/A | almost 3 years ago | $27 152.80% upside | $17.68 | Benzinga | N/A |
Unknown Piper Sandler | N/A | almost 3 years ago | $34 218.35% upside | $21.98 | Benzinga | N/A |
Zegbeh Jallah Capital One Financial | 0% 0/1 | about 3 years ago | $48 349.43% upside | $24.17 | TheFly | Previous targets (0) |
RAPT Therapeutics Financial Estimates
RAPT Therapeutics Revenue Estimates
RAPT Therapeutics EBITDA Estimates
RAPT Therapeutics Earnings per Share Estimates
| Passed | Analyst forecast | ||||||
|---|---|---|---|---|---|---|---|
| Metric | 12/31/2021 | 12/31/2022 | 12/31/2023 | 12/31/2025 | 12/31/2026 | 12/31/2027 | 12/31/2028 |
Revenue
% change YoY
| $3.81M N/A | $1.52M -59.95% | $0 -100% | Avg: $768.35K Low: $768.35K High: $768.35K avg. 0% | Avg: $16.43M Low: $16.43M High: $16.43M avg. 2038.78% | Avg: $202.5M Low: $202.5M High: $202.5M avg. 1132.25% | Avg: $311.6M Low: $311.6M High: $311.6M avg. 53.87% |
Net Income
% change YoY
| $-68.20M N/A | $-81.88M -20.04% | $-116.79M -42.64% | Avg: $-132.05M Low: $-190.15M High: $-41.40M avg. -13.06% | Avg: $-234.86M Low: $-268.75M High: $-63.65M avg. -77.84% | Avg: $-18.01M Low: $-18.01M High: $-18.01M avg. 92.32% | Avg: $38.33M Low: $38.33M High: $38.33M avg. 312.76% |
EBITDA
% change YoY
| $-69.20M N/A | $-85.79M -23.96% | $-125.84M -46.68% | Avg: $-153.66K Low: $-153.66K High: $-153.66K avg. 99.87% | Avg: $-3.28M Low: $-3.28M High: $-3.28M avg. -2038.79% | Avg: $-40.49M Low: $-40.49M High: $-40.49M avg. -1132.25% | Avg: $-62.31M Low: $-62.31M High: $-62.31M avg. -53.87% |
EPS
% change YoY
| -$2.49 N/A | -$2.52 -1.20% | -$3.05 -21.03% | Avg: -$2.64 Low: -$4.96 High: -$1.08 avg. 13.54% | Avg: -$3.73 Low: -$7.01 High: -$1.66 avg. -41.36% | Avg: -$0.47 Low: -$0.47 High: -$0.47 avg. 87.39% | Avg: $1 Low: $1 High: $1 avg. 312.76% |
Operating Expenses
% change YoY
| $73.02M N/A | $87.32M 19.58% | $127.06M 45.50% | Avg: $3.37M Low: $3.37M High: $3.37M avg. -97.34% | Avg: $72.28M Low: $72.28M High: $72.28M avg. 2038.78% | Avg: $890.73M Low: $890.73M High: $890.73M avg. 1132.25% | Avg: $1.37B Low: $1.37B High: $1.37B avg. 53.87% |
FAQ
What is RAPT Therapeutics stock earnings growth forecast?
Wall Street analysts estimate the annual average earnings growth rate of 78.54% in 2025-2028.
We have gathered data from 7 analysts. Their low estimate is -190.15M, average is -132.05M and high is -41.40M.
What is RAPT Therapeutics stock revenue growth forecast?
Wall Street analysts forecast annual average revenue growth of 806.22% in 2025-2028.
We have gathered data from 6 analysts. Their low revenue estimate is $768.35K, average is $768.35K and high is $768.35K.
What is RAPT Therapeutics stock earnings per share growth forecast?
Wall Street analysts forecast annual average earnings growth of 93.08% in 2025-2028.
We have gathered data from 7 analysts. Their low earnings per share estimate is -$4.96, average is -$2.64 and high is $-1.08.
What is the best performing analyst?
In the last twelve months 2 analysts have been covering RAPT Therapeutics stock. The most successful analyst is Alex Thompson.